STOCK TITAN

HSKA - HSKA STOCK NEWS

Welcome to our dedicated page for HSKA news (Ticker: HSKA), a resource for investors and traders seeking the latest updates and insights on HSKA stock.

Heska Corporation (NASDAQ: HSKA) is a leading provider of advanced veterinary diagnostic and imaging solutions. The company is dedicated to enhancing the quality of pet care through cutting-edge technology and comprehensive services. Founded by veterinary professionals for veterinary professionals, Heska is committed to upholding sound science and best medical practices.

Core Areas of Expertise:

  • Diagnostic Systems: Heska offers state-of-the-art chemistry, hematology, and blood gas & electrolyte systems designed to deliver precise and reliable results.
  • Imaging Solutions: The company leads the field with advanced HD digital radiography, digital ultrasound, and PACS imaging technologies from Cuattro, facilitating more accurate diagnoses and effective treatments.
  • Allergy & Renal Health: Heska provides specialized diagnostics for heartworm, early renal healthscreens, and comprehensive allergy testing and treatment options.

Headquartered in Loveland, Colorado, Heska serves veterinary practices worldwide, helping them improve patient care, productivity, and profitability. The company is known for its innovative products that meet the evolving needs of veterinary professionals.

Recent Achievements:

  • Heska's partnership with Dalan Animal Health, Inc. to further expand their diagnostic capabilities.
  • Introduction of new products aimed at enhancing diagnostic accuracy and efficiency in veterinary practices.

With a focus on excellence and a pledge to support veterinary practices, Heska continues to make significant strides in pet healthcare technology.

Rhea-AI Summary

Heska Corporation (NASDAQ: HSKA) will announce its first quarter 2021 financial results on May 6, 2021, before the market opens. An earnings call is scheduled for 9 a.m. MT (11 a.m. ET) to discuss the results. Investors can access the call via phone or through a live webcast on the Company's investor relations website. A telephonic replay will be available shortly after the call until May 20, 2021. Heska offers advanced veterinary diagnostic products, focusing on North America and international segments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Heska Corporation (NASDAQ: HSKA) has announced an underwritten public offering of 940,860 shares of its common stock priced at $186.00 per share, totaling approximately $175 million in gross proceeds. The offering size was increased from $150 million to $175 million, with an option for underwriters to purchase an additional 141,129 shares. Proceeds will be used for general corporate purposes, including product development and potential acquisitions. The offering is expected to close on or around March 5, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Heska Corporation (NASDAQ: HSKA) has initiated an underwritten public offering of $150 million in common stock, with plans to provide underwriters a 30-day option for an additional 15% of shares sold. The funds will be used for general corporate purposes, including working capital, product development, and potential acquisitions, although no specific agreements are in place. The offering is subject to market conditions, and details will be filed with the SEC. J.P. Morgan and Piper Sandler & Co. are the joint book-running managers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Heska Corporation (NASDAQ: HSKA) reported exceptionally strong financial results for Q4 and FY 2020. Consolidated revenue reached $64.3 million, up 90.5% year-over-year, and $197.3 million for the full year, a 60.9% increase. North America saw revenue grow by 29.3% in Q4 and 13.6% annually. The company successfully expanded its subscription services, achieving a 25% increase in active subscriptions in 2020. Despite challenges in international segments, overall gross margin remained resilient. Heska has set ambitious revenue guidance for 2021, forecasting $225-$235 million in consolidated revenue.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Heska Corporation (NASDAQ: HSKA), a leader in veterinary diagnostics, announced that CEO Kevin Wilson will present at several upcoming conferences in February and March 2021. Key events include the Bank of America Securities 2021 Virtual Animal Health Summit on February 25, Raymond James 42nd Annual Institutional Investors Conference on March 1, and Barclays Global Healthcare Conference on March 9. Each presentation will be accessible via webcast, and replays will be available for 90 days. Heska specializes in advanced veterinary diagnostic and specialty products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Heska Corporation (NASDAQ: HSKA) will report its Q4 and full-year 2020 financial results on February 23, 2021, before market opening. An earnings call is scheduled for 9 a.m. MT / 11 a.m. ET to discuss the results. The call can be accessed via phone or through a live webcast on the company's investor relations website. A replay will be available after the call. Heska specializes in advanced veterinary diagnostic products across North America and internationally, providing various healthcare solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Heska Corporation (NASDAQ: HSKA) announced its acquisition of Lacuna Diagnostics, a leader in point-of-care digital cytology technology and telemedicine. The deal, expected to close in Q1 2021, aims to enhance Heska's clinical specialty services, aligning with its goal to double product and revenue streams. Lacuna's innovative platform allows veterinarians to get rapid, expert analysis of diagnostic samples, improving care outcomes. This collaboration is poised to expand service reach and positively impact veterinary diagnostics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Heska Corporation (NASDAQ: HSKA) has appointed Dr. Joachim Hasenmaier, former head of Boehringer Ingelheim Animal Health, to its Board of Directors effective January 11, 2021. Dr. Hasenmaier brings extensive experience in animal health, having overseen significant growth and acquisitions at Boehringer Ingelheim. His expertise is expected to enhance Heska's strategic execution and global positioning in the veterinary diagnostics market. CEO Kevin Wilson expressed enthusiasm, noting Hasenmaier's capability to foster innovation and growth while benefiting shareholders and the broader animal health industry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary

Heska Corporation (NASDAQ: HSKA) announced that CEO Kevin Wilson will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 2 p.m. ET. Registered attendees can view the presentation live, while audio-only access is available for non-registered individuals. The session will include a Q&A segment. Additionally, Heska's management will hold one-on-one meetings on the same date, with contacts provided for meeting requests. Post-event, a webcast of the presentation will be archived on Heska's website for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

Heska Corporation (NASDAQ: HSKA) announced that President & CEO Kevin Wilson will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020. The presentation will be available for registered attendees from November 23 to December 3, with an archived replay on Heska's website for 90 days afterward. Alongside the presentation, Mr. Wilson will hold one-on-one meetings on the conference day, which can be arranged through Piper Sandler or Heska Investor Relations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences

FAQ

What is the market cap of HSKA (HSKA)?

The market cap of HSKA (HSKA) is approximately 1.3B.

What does Heska Corporation specialize in?

Heska Corporation specializes in advanced veterinary diagnostic and imaging solutions, including chemistry, hematology, and blood gas systems, as well as HD digital radiography and digital ultrasound technologies.

Where is Heska Corporation headquartered?

Heska Corporation is headquartered in Loveland, Colorado.

Who founded Heska Corporation?

Heska was founded by veterinary professionals for veterinary professionals.

What are Heska’s main products?

Heska's main products include diagnostic systems for chemistry, hematology, and blood gas, as well as imaging solutions like HD digital radiography, digital ultrasound, and PACS imaging technologies.

What recent achievements has Heska Corporation made?

Recent achievements include a partnership with Dalan Animal Health, Inc. and the introduction of new products aimed at enhancing diagnostic accuracy and efficiency.

How does Heska support veterinary practices?

Heska supports veterinary practices by providing innovative diagnostic and imaging solutions that improve patient care, productivity, and profitability.

What sets Heska apart from other veterinary diagnostic companies?

Heska sets itself apart through its commitment to sound science, best medical practices, and its comprehensive range of state-of-the-art diagnostic and imaging products.

What types of diagnostic systems does Heska offer?

Heska offers diagnostic systems for chemistry, hematology, blood gas & electrolyte, heartworm, and early renal healthscreens.

What imaging technologies does Heska provide?

Heska provides HD digital radiography, digital ultrasound, and PACS imaging technologies under the Cuattro brand.

How does Heska ensure the quality of its products?

Heska ensures the quality of its products by upholding sound science and following best medical practices, along with a dedication to continuous innovation.

HSKA

Nasdaq:HSKA

HSKA Rankings

HSKA Stock Data

1.31B
10.24M
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Loveland